Impax Asset Management Group plc Has $2.54 Million Stake in Intuitive Surgical, Inc. (NASDAQ:ISRG)

Impax Asset Management Group plc increased its stake in shares of Intuitive Surgical, Inc. (NASDAQ:ISRG - Free Report) by 43.9% in the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 5,167 shares of the medical equipment provider's stock after buying an additional 1,577 shares during the quarter. Impax Asset Management Group plc's holdings in Intuitive Surgical were worth $2,538,000 at the end of the most recent quarter.

A number of other hedge funds also recently added to or reduced their stakes in the stock. Mirador Capital Partners LP increased its position in Intuitive Surgical by 1.4% in the 3rd quarter. Mirador Capital Partners LP now owns 3,526 shares of the medical equipment provider's stock valued at $1,732,000 after acquiring an additional 50 shares during the period. Advisors Asset Management Inc. increased its holdings in shares of Intuitive Surgical by 18.1% during the first quarter. Advisors Asset Management Inc. now owns 7,380 shares of the medical equipment provider's stock valued at $2,945,000 after purchasing an additional 1,129 shares during the period. Consolidated Planning Corp raised its stake in shares of Intuitive Surgical by 17.4% during the third quarter. Consolidated Planning Corp now owns 8,099 shares of the medical equipment provider's stock valued at $3,979,000 after purchasing an additional 1,198 shares in the last quarter. Healthcare of Ontario Pension Plan Trust Fund grew its position in Intuitive Surgical by 617.1% in the 2nd quarter. Healthcare of Ontario Pension Plan Trust Fund now owns 89,069 shares of the medical equipment provider's stock valued at $39,622,000 after buying an additional 76,649 shares in the last quarter. Finally, Brookstone Capital Management increased its stake in Intuitive Surgical by 22.4% during the 2nd quarter. Brookstone Capital Management now owns 12,530 shares of the medical equipment provider's stock valued at $5,340,000 after buying an additional 2,289 shares during the period. 83.64% of the stock is currently owned by institutional investors.

Intuitive Surgical Stock Down 1.9 %

Shares of Intuitive Surgical stock traded down $10.19 during midday trading on Friday, hitting $527.61. The company's stock had a trading volume of 1,447,901 shares, compared to its average volume of 1,417,223. Intuitive Surgical, Inc. has a 1-year low of $295.02 and a 1-year high of $544.38. The stock has a 50-day simple moving average of $499.29 and a 200-day simple moving average of $457.89. The firm has a market capitalization of $187.92 billion, a P/E ratio of 84.82, a PEG ratio of 5.19 and a beta of 1.39.

Intuitive Surgical (NASDAQ:ISRG - Get Free Report) last posted its quarterly earnings results on Thursday, October 17th. The medical equipment provider reported $1.56 EPS for the quarter, topping the consensus estimate of $1.24 by $0.32. The business had revenue of $2.04 billion during the quarter, compared to analysts' expectations of $2.01 billion. Intuitive Surgical had a net margin of 28.51% and a return on equity of 13.41%. As a group, sell-side analysts predict that Intuitive Surgical, Inc. will post 5.45 earnings per share for the current year.

Wall Street Analysts Forecast Growth

Several research firms have recently issued reports on ISRG. Leerink Partners increased their price objective on shares of Intuitive Surgical from $489.00 to $502.00 in a report on Thursday, October 17th. Stifel Nicolaus increased their price target on Intuitive Surgical from $475.00 to $525.00 and gave the company a "buy" rating in a research note on Friday, October 18th. Robert W. Baird boosted their price objective on Intuitive Surgical from $503.00 to $565.00 and gave the stock an "outperform" rating in a research note on Thursday, October 17th. Piper Sandler reaffirmed an "overweight" rating and set a $538.00 target price (up previously from $495.00) on shares of Intuitive Surgical in a research note on Friday, October 18th. Finally, Truist Financial boosted their price target on shares of Intuitive Surgical from $520.00 to $570.00 and gave the stock a "buy" rating in a research report on Monday, October 14th. One investment analyst has rated the stock with a sell rating, five have assigned a hold rating and fourteen have given a buy rating to the company. Based on data from MarketBeat, the company currently has a consensus rating of "Moderate Buy" and a consensus target price of $513.74.

Insider Buying and Selling at Intuitive Surgical

In related news, SVP Henry L. Charlton sold 40,243 shares of the stock in a transaction on Friday, August 23rd. The stock was sold at an average price of $486.84, for a total transaction of $19,591,902.12. Following the completion of the sale, the senior vice president now directly owns 3,001 shares in the company, valued at approximately $1,461,006.84. This trade represents a 93.06 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, EVP Robert Desantis sold 188 shares of the business's stock in a transaction dated Thursday, August 29th. The shares were sold at an average price of $482.21, for a total value of $90,655.48. Following the completion of the transaction, the executive vice president now owns 5,506 shares in the company, valued at $2,655,048.26. This trade represents a 3.30 % decrease in their position. The disclosure for this sale can be found here. Insiders sold 91,178 shares of company stock valued at $45,897,071 in the last quarter. Company insiders own 0.90% of the company's stock.

Intuitive Surgical Profile

Intuitive Surgical, Inc develops, manufactures, and markets products that enable physicians and healthcare providers to enhance the quality of and access to minimally invasive care in the United States and internationally. The company offers the da Vinci Surgical System that enables complex surgery using a minimally invasive approach; and Ion endoluminal system, which extends its commercial offerings beyond surgery into diagnostic procedures enabling minimally invasive biopsies in the lung.